We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Senate late Saturday approved a spending bill that gives the FDA nearly $1.7 billion in drug and biologic regulatory funding, a $48 million increase over current levels. Read More
Generic drug prices in Canada have fallen significantly in recent years, even while they continue to trend higher than their international cohorts, says a new Canadian government report. Read More
The FDA has approved Eli Lilly’s Cyramza to treat the most common type of lung cancer, the latest effort by the drugmaker to vastly increase uses of the oncology drug. Read More
A federal judge has ordered Actavis to keep the original version of its blockbuster Alzheimer’s therapy Namenda on the market while the court hears an ongoing antitrust lawsuit that claims the drugmaker wants to pull the older version to hinder generic competition. Read More
The drug pricing authority in India added 52 more drugs under price control, including products used to treat pain, cancer, skin disorders and infections, as part of a program to provide life-saving and essential medicine's to the country’s population. Read More
India’s health ministry is proposing to spend more than $280 million to strengthen the country’s national and state drug regulatory systems, with the aim of speeding approval decisions and testing of products. Read More
The House late last night approved nearly $1.7 billion in funding for FDA’s drug and biologics activities next year, a slight boost from current levels. Read More
For the first time, a brand drugmaker has defeated a generics firm’s patent challenge through the U.S. Patent and Trademark Office’s internal review board process, which started in 2012. Read More
The FDA has approved 35 novel new drugs so far this year, up from 27 products last year, with officials touting 2014 as the best year ever for rare disease treatment approvals. Read More
A recent FDA inspection of contract research organization GVK Biosciences’ Hyderabad, India, plant turned up no evidence of safety or efficacy concerns with US-bound generic therapies, a finding that is in sharp contrast to initial conclusions reached by European inspectors. Read More
A large public employer has filed a federal class-action lawsuit accusing Gilead Sciences of price gouging with its $1,000-a-pill hepatitis C drug Sovaldi. Read More